Insider Transactions in Q3 2021 at Heron Therapeutics, Inc. (HRTX)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 21
2021
|
Craig A Johnson Director |
SELL
Open market or private sale
|
Direct |
250
-7.49%
|
$3,000
$12.3 P/Share
|
|
Sep 21
2021
|
Waage Christian Director |
SELL
Open market or private sale
|
Direct |
300
-7.89%
|
$3,600
$12.31 P/Share
|
|
Jul 13
2021
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-15.01%
|
$5,629
$13.48 P/Share
|
|
Jul 13
2021
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+30.24%
|
-
|
|
Jul 13
2021
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
191
-1.36%
|
$2,483
$13.48 P/Share
|
|
Jul 13
2021
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
552
+3.79%
|
-
|
|
Jul 13
2021
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-1.91%
|
$5,629
$13.48 P/Share
|
|
Jul 13
2021
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+5.23%
|
-
|
|
Jul 13
2021
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
963
-0.96%
|
$12,519
$13.48 P/Share
|
|
Jul 13
2021
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,645
+3.5%
|
-
|
|
Jul 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-12.04%
|
$5,629
$13.48 P/Share
|
|
Jul 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+25.79%
|
-
|